Search Here

The White House's discount drug platform TrumpRx is expanding, with AbbVie and Genentech joining the program to offer lower-cost medications starting Monday.

The two companies become the 10th and 11th drugmakers to participate in the initiative, which aims to reduce prescription prices for uninsured Americans.

The platform now lists more than 61 medications, up from about 40 when it launched earlier this year.

AbbVie will provide its widely used drug Humira at a steep discount.

The medication, commonly prescribed for rheumatoid arthritis, Crohn's disease, and ulcerative colitis, can cost over $6,900 for uninsured patients.

Through TrumpRx, the price will drop to about $950, an 86% reduction.

According to NT, Genentech is also lowering the cost of its flu treatment Xofluza. The single-dose pill will be available for around $50, down from its usual price of $168.

Officials say the program is designed mainly for people without insurance or those whose plans do not cover certain prescriptions.

Patients with insurance often already pay lower prices, so the discounts are targeted at those who would otherwise pay full cost out of pocket.

TrumpRx Expansion Tied to New Healthcare Plan

A White House official said the administration is working to expand access further through a proposed "Great Healthcare Plan."

The plan would allow people with government insurance to use copays for drugs purchased through TrumpRx, though Congress has not yet acted on the proposal.

The platform is part of a broader push by Donald Trump's administration to lower drug prices using "most-favored-nation" agreements, CBS News reported.

These deals aim to match US drug prices with lower prices offered in other countries.

Another drugmaker, Amgen, is also expanding its presence on the site. It plans to add medications like Enbrel for arthritis and Otezla for plaque psoriasis, giving patients more options at reduced prices.

The growing list of discounted drugs shows how quickly the program is evolving. For patients who struggle to afford medicine, the lower prices could make a real difference.

Still, access remains limited to certain groups, and the long-term impact will depend on whether more companies join and whether lawmakers approve plans to widen eligibility.